Chapter 11: Future directions in cervical pathology.
Technologic innovations, including the development of improved sampling devices, liquid-based collection systems, and computer-assisted screening, have revolutionized cervical cytology. Biologic discoveries in upcoming years promise to transform our understanding of the pathogenesis of cervical neoplasia, leading to another quantum leap in our approach to screening and prevention. This review summarizes the opportunities and challenges that recent and anticipated advances in pathology present for epidemiologic research.
Sherman
Mark E
ME
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health/DHHS, 6120 Executive Boulevard, Rm. 7080, EPS MSC 7234, Bethesda, MD 20892-7234, USA. shermanm@mail.nih.gov
D000230:Adenocarcinoma / Q000175:diagnosis; D003127:Colposcopy; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000639:trends*; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000175:diagnosis; D014218:Triage; D014412:Tumor Virus Infections / Q000175:diagnosis; D002577:Uterine Cervical Diseases / Q000175:diagnosis* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis
D004279:DNA, Viral